MCID: RNL015
MIFTS: 48

Renal Hypertension

Categories: Cardiovascular diseases, Ear diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Hypertension

MalaCards integrated aliases for Renal Hypertension:

Name: Renal Hypertension 12 74 15 17 71
Hypertension, Renal 43
Hypertension Renal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1073
MeSH 43 D006977
NCIt 49 C3121
SNOMED-CT 67 28119000
UMLS 71 C0020544

Summaries for Renal Hypertension

MalaCards based summary : Renal Hypertension, also known as hypertension, renal, is related to malignant hypertensive renal disease and chronic pyelonephritis. An important gene associated with Renal Hypertension is EDN1 (Endothelin 1), and among its related pathways/superpathways are Pathways in cancer and Development Angiotensin activation of ERK. The drugs Indapamide and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renal Hypertension

Diseases in the Renal Hypertension family:

Renal Failure, Progressive, with Hypertension

Diseases related to Renal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 34.2 REN EDN1 AGTR1
2 chronic pyelonephritis 30.8 REN ALB ACE
3 hypertensive nephropathy 30.8 ALB AGTR1 ACE
4 familial hypertension 30.6 REN AGTR1 AGT
5 hypertension, diastolic 30.6 REN ACE
6 uremia 30.5 REN EPO ALB ACE
7 acute kidney failure 30.5 REN KNG1 ALB
8 renovascular hypertension 30.5 REN NPPB NOS3 EDN1 AGTR1 ADM
9 pure autonomic failure 30.4 REN EPO DBH ACE
10 fibromuscular dysplasia 30.3 REN AGTR1 AGT ACE
11 nephrosclerosis 30.3 AGTR1 ACE2 ACE
12 malignant essential hypertension 30.3 REN KNG1 KLKB1 ACE
13 cystic kidney disease 30.3 REN EPO ALB ACE
14 renal fibrosis 30.2 REN MIR200B ALB AGTR1 AGT
15 atherosclerosis susceptibility 30.2 NOS3 EDN1 ALB AGTR1 ACE
16 hypertensive retinopathy 30.2 REN ALB AGTR1 ACE
17 microvascular complications of diabetes 3 30.2 REN ALB AGTR1 ACE
18 hypertensive encephalopathy 30.1 REN EPO ALB AGTR1 ACE
19 intracranial hypertension 30.1 SLC12A3 NPPB ALB
20 malignant renovascular hypertension 30.1 REN EDN1 AGTR1
21 malignant hypertension 30.1 REN NPPB EDN1 AGTR1 AGT ADM
22 coronary stenosis 30.1 NPPB ALB ACE
23 hepatorenal syndrome 30.0 REN EDN1 ALB ACE
24 hypokalemia 30.0 SLC12A3 REN ALB ACE
25 liver cirrhosis 30.0 REN KLKB1 EDN1 ALB ADM
26 gitelman syndrome 29.9 SLC12A3 REN AGT
27 focal segmental glomerulosclerosis 29.9 APOL1 ALB AGTR1 ACE
28 urinary tract obstruction 29.9 REN ALB AGTR1 ACE
29 liddle syndrome 1 29.9 SLC12A3 REN AGT
30 pheochromocytoma 29.9 REN KNG1 EPO EDN1 DBH ADM
31 portal hypertension 29.8 NOS3 EDN1 ALB AGTR1 ACE
32 renal tubular dysgenesis 29.7 REN AGTR1 AGT ACE
33 renal dysplasia 29.7 REN AGTR1 AGT ACE
34 retinal vascular disease 29.7 REN NOS3 EDN1 ALB ACE
35 peripheral vascular disease 29.6 NOS3 KNG1 EPO ALB ACE
36 coronary heart disease 1 29.6 NPPB NOS3 EDN1 AGTR1 ACE
37 end stage renal failure 29.6 REN NPPB EPO ALB AGTR1 AGT
38 interstitial nephritis 29.6 REN ALB AGTR1 AGT ACE
39 kidney hypertrophy 29.5 REN NOS3 ALB ACE2 ACE
40 ischemia 29.5 NPPB NOS3 KNG1 EPO EDN1 ACE
41 pulmonary hypertension 29.4 REN NPPB NOS3 EDN1 ALB AGTR1
42 sleep apnea 29.4 REN NPPB NOS3 EPO EDN1 ALB
43 polycystic kidney disease 29.3 REN NOS3 EPO EDN1 ALB AGTR1
44 diastolic heart failure 29.2 REN NPPB NOS3 AGTR1 AGT ACE
45 eclampsia 29.1 REN NOS3 EDN1 ALB AGTR1 AGT
46 autosomal dominant polycystic kidney disease 29.1 REN NOS3 EDN1 ALB AGTR1 AGT
47 vascular disease 29.0 REN NPPB NOS3 KNG1 EPO EDN1
48 body mass index quantitative trait locus 11 29.0 REN NOS3 KNG1 EDN1 ALB AGT
49 renal artery disease 29.0 REN NOS3 EPO APOL1 ALB AGTR1
50 pre-eclampsia 29.0 REN NOS3 KNG1 EDN1 ALB AGTR1

Graphical network of the top 20 diseases related to Renal Hypertension:



Diseases related to Renal Hypertension

Symptoms & Phenotypes for Renal Hypertension

MGI Mouse Phenotypes related to Renal Hypertension:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ACE2 ADM AGT AGTR1 ALB
2 homeostasis/metabolism MP:0005376 9.97 ACE ACE2 ADM AGT AGTR1 ALB
3 muscle MP:0005369 9.56 ACE2 ADM AGT ALB EDN1 EPO
4 renal/urinary system MP:0005367 9.32 ACE ACE2 ADM AGT AGTR1 ALB

Drugs & Therapeutics for Renal Hypertension

Drugs for Renal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indapamide Approved Phase 4 26807-65-8 3702
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Captopril Approved Phase 4 62571-86-2 44093
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Bisoprolol Approved Phase 4 66722-44-9 2405
9
Candesartan Experimental Phase 4 139481-59-7 2541
10 Angiotensin-Converting Enzyme Inhibitors Phase 4
11 Sodium Chloride Symporter Inhibitors Phase 4
12 Angiotensin Receptor Antagonists Phase 4
13 HIV Protease Inhibitors Phase 4
14
protease inhibitors Phase 4
15 Angiotensin II Type 1 Receptor Blockers Phase 4
16 Giapreza Phase 4
17 Angiotensinogen Phase 4
18 Hormones Phase 4
19 Neurotransmitter Agents Phase 4
20 Adrenergic Antagonists Phase 4
21 Adrenergic beta-1 Receptor Antagonists Phase 4
22 Vasodilator Agents Phase 4
23 Autonomic Agents Phase 4
24 Sympatholytics Phase 4
25 Adrenergic Agents Phase 4
26
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
27
Lisinopril Approved, Investigational Phase 3 83915-83-7, 76547-98-3 5362119
28
Losartan Approved Phase 3 114798-26-4 3961
29
Atenolol Approved Phase 3 29122-68-7 2249
30
Hydralazine Approved Phase 3 86-54-4 3637
31
Minoxidil Approved, Investigational Phase 3 38304-91-5 4201
32
Diltiazem Approved, Investigational Phase 3 42399-41-7 39186
33
Metoprolol Approved, Investigational Phase 3 51384-51-1, 37350-58-6 4171
34
Clonidine Approved Phase 3 4205-90-7 2803
35
Magnesium citrate Approved Phase 3 3344-18-1
36
Sodium citrate Approved, Investigational Phase 3 68-04-2
37
Bevacizumab Approved, Investigational Phase 3 216974-75-3
38
Bisacodyl Approved Phase 3 603-50-9
39
Dimenhydrinate Approved Phase 3 523-87-5 441281
40
Chlorothiazide Approved, Vet_approved Phase 3 58-94-6 2720
41
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
42
Mycophenolic acid Approved Phase 3 24280-93-1 446541
43
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
44
tannic acid Approved Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
46
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
48 Antihypertensive Agents Phase 3
49 LCZ 696 Phase 3
50 Calcium, Dietary Phase 3

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension Completed NCT01656096 Phase 4
2 A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension Completed NCT01172431 Phase 4 Indapamide;Hydrochlorothiazide
3 An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus Completed NCT00660309 Phase 4 Aliskiren;Irbesartan;Captopril
4 Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial. Completed NCT01734096 Phase 4 Candesartan cilexetil
5 Renal Denervation in Patients With Resistant Hypertension Completed NCT01570777 Phase 4
6 Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. Recruiting NCT04085562 Phase 4 Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg
7 Renal Denervation for Complicated Hypertension (RDNP-2012-03) Terminated NCT01865253 Phase 4
8 Renal Denervation for Resistant Hypertension Terminated NCT01865240 Phase 4
9 DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY Unknown status NCT01522430 Phase 3
10 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
11 Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection Unknown status NCT00868972 Phase 2, Phase 3
12 A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction Completed NCT01593787 Phase 3 LCZ696
13 Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial Completed NCT01850901 Phase 3
14 Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome Completed NCT00723801 Phase 3 Atenolol;Losartan
15 Polycystic Kidney Disease-Treatment Network Completed NCT01885559 Phase 3 Lisinopril;Telmisartan;Placebo
16 Polycystic Kidney Disease-Treatment Network Completed NCT00283686 Phase 3 Lisinopril;Telmisartan;Placebo
17 Treatment of Masked Hypertension Completed NCT02142881 Phase 3
18 A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy Completed NCT01778192 Phase 3 Polyethylene glycol;Polyethylene glycol;Sodium picosulphate with magnesium citrate;Sodium picosulphate with magnesium citrate
19 Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy Completed NCT00656435 Phase 3 Bevacizumab
20 Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation Completed NCT03074448 Phase 3 Sodium Picosulfate
21 Treatment of Hypertension Completed NCT00000484 Phase 3 chlorothiazide;Rauwolfia alkaloids
22 A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension Recruiting NCT02910414 Phase 3 Dehydrated alcohol
23 Renal Denervation Using the OneShot Ablation System Terminated NCT01844037 Phase 2, Phase 3
24 Renal Denervation - Hope for Patients With Refractory Hypertension? Terminated NCT01560312 Phase 3
25 Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial Terminated NCT01762488 Phase 3
26 Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation Terminated NCT00151632 Phase 3 Mycophenolate mofetil;Tacrolimus
27 Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II Withdrawn NCT01939392 Phase 2, Phase 3
28 High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure Unknown status NCT02608632 Phase 2
29 Renal Denervation in Patients With Uncontrolled Hypertension in Chinese Unknown status NCT01390831 Phase 1, Phase 2
30 Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study) Unknown status NCT02002585 Phase 2
31 Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension Unknown status NCT01505010 Phase 2
32 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
33 The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant Completed NCT00446459 Phase 2 mycophenolate mofetil (CellCept)
34 The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Completed NCT00446251 Phase 2 Rituximab;Mycophenolate mofetil (MMF)
35 A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications Recruiting NCT03503773 Phase 2 Alcohol
36 Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF) Recruiting NCT02432339 Phase 1, Phase 2 mycophenolate mofetil (MMF);Placebo
37 Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography Active, not recruiting NCT01673516 Phase 2
38 A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure Terminated NCT03152552 Phase 2 LIK066;Placebo;Empagliflozin
39 Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension Terminated NCT02653222 Phase 2
40 A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157) Completed NCT02095691 Phase 1
41 A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02) Completed NCT01756300 Phase 1
42 Renal Denervation in Patients With Refractory Hypertension Completed NCT00483808 Phase 1
43 Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients Completed NCT01491919 Phase 1 Lisinopril
44 Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy. Completed NCT00743210 Phase 1 L-citrulline;Placebo
45 Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation Unknown status NCT02164435
46 Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study) Unknown status NCT01785732
47 Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension Unknown status NCT02029885
48 Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension Unknown status NCT02480517
49 Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter Unknown status NCT02115230
50 A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension Unknown status NCT02690909

Search NIH Clinical Center for Renal Hypertension

Cochrane evidence based reviews: hypertension, renal

Genetic Tests for Renal Hypertension

Anatomical Context for Renal Hypertension

MalaCards organs/tissues related to Renal Hypertension:

40
Kidney, Heart, Liver, Testes, Endothelial, Brain, Skin

Publications for Renal Hypertension

Articles related to Renal Hypertension:

(show top 50) (show all 3180)
# Title Authors PMID Year
1
[Management of renal atrophy in hypertensive patients: experience in Lille]. 54 61
19854024 2010
2
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. 54 61
16982943 2006
3
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. 54 61
16168275 2005
4
Association study of calcitonin-receptor-like receptor gene in essential hypertension. 54 61
15797661 2005
5
The clinical use of angiotensin-converting enzyme inhibitors. 54 61
15586352 2004
6
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? 54 61
12437489 2002
7
Methods for assessing endothelin ETA-receptor antagonists in preclinical studies. 54 61
12224443 2002
8
Endothelin and heart failure. 54 61
11447308 2001
9
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. 54 61
11675775 2001
10
Development of ideas on renovascular hypertension. 54 61
11022890 2000
11
[The protection of renal function in the ACEI treatment of renal hypertension]. 54 61
12206011 2000
12
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 54 61
10604545 1999
13
[Adrenomedullin]. 54 61
10352550 1999
14
[Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function]. 54 61
12080656 1999
15
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. 54 61
9796839 1998
16
Endothelin as a regulator of cardiovascular function in health and disease. 54 61
9794709 1998
17
Adrenomedullin: a new modulator of vascular tone. 54 61
8951571 1996
18
Adrenomedullin: a new hypotensive peptide. 54 61
9120666 1996
19
[Arterial hypertension in patients on chronic hemodialysis]. 54 61
9102857 1996
20
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. 54 61
8743512 1996
21
[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. 54 61
8686202 1996
22
Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. 54 61
8846416 1995
23
Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. 54 61
7473533 1995
24
[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]. 54 61
7638769 1995
25
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. 54 61
8143425 1994
26
Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. 54 61
8485747 1993
27
Urinary kallikrein excretion is low in malignant essential hypertension. 54 61
1325521 1992
28
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 54 61
1908620 1991
29
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. 61
31961420 2020
30
Renal sympathetic nerve activity regulates cardiovascular energy expenditure in rats fed high salt. 61
31932643 2020
31
Editor's Choice - Comorbidity Patterns Among Patients with Peripheral Arterial Occlusive Disease in Germany: A Trend Analysis of Health Insurance Claims Data. 61
31744786 2020
32
Afferent innervation of the ischemic kidney contributes to renal dysfunction in renovascular hypertensive rats. 61
31925527 2020
33
NOX2-derived reactive oxygen species in immune cells exacerbates salt-sensitive hypertension. 61
31730933 2020
34
Correlations between Interleukin-11 expression and hypertensive kidney injury in a rat model of renovascular hypertension. 61
31840157 2019
35
Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males. 61
31704553 2019
36
The Demystification of Secondary Hypertension: Diagnostic Strategies and Treatment Algorithms. 61
31823067 2019
37
Importance of infarct size versus other variables for clinical outcomes after PPCI in STEMI patients. 61
31832789 2019
38
Posterior Reversible Encephalopathy Syndrome in adult sickle-cell patients: Case series and literature review. 61
31447365 2019
39
Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus. 61
30892934 2019
40
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. 61
31682908 2019
41
Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. 61
31264765 2019
42
Human nephron number, hypertension, and renal pathology. 61
31729838 2019
43
Resistant hypertension: Renal denervation or pharmacovigilance? Insights from a renal denervation screening program. 61
31693316 2019
44
Hyperglycemia-induced posterior reversible encephalopathy syndrome: A rare cause of reversible blindness. 61
31742185 2019
45
Intracranial vascular pathology in two further patients with Floating-Harbor syndrome: Proposals for cerebrovascular disease risk management. 61
31605816 2019
46
Predictors and outcomes of bleed after sleeve gastrectomy: an analysis of the MBSAQIP data registry. 61
31590999 2019
47
International comparison of trends in patients commencing renal replacement therapy by primary renal disease. 61
30456883 2019
48
Dietary Effects on Dahl Salt-Sensitive Hypertension, Renal Damage, and the T Lymphocyte Transcriptome. 61
31476910 2019
49
Two Cases of Endovascular Repair with the Stent Graft for Retrograde Type A Acute Aortic Dissection with Complications. 61
29503377 2019
50
TRPV1 (Transient Receptor Potential Vanilloid 1) Cardiac Spinal Afferents Contribute to Hypertension in Spontaneous Hypertensive Rat. 61
31422690 2019

Variations for Renal Hypertension

Expression for Renal Hypertension

Search GEO for disease gene expression data for Renal Hypertension.

Pathways for Renal Hypertension

Pathways related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1 12.63 KNG1 EPO EDN1 AGTR1 AGT
2
Show member pathways
12.59 NOS3 EPO EDN1 AGTR1 AGT
3
Show member pathways
12.27 NPPB NOS3 KNG1 AGTR1 AGT
4
Show member pathways
12.09 NPPB NOS3 EDN1 AGTR1 AGT ADM
5
Show member pathways
12.04 REN AGT ACE2 ACE
6 11.62 NOS3 EDN1 AGTR1 AGT
7 11.48 EPO EDN1 ADM
8 11.37 NOS3 EPO EDN1
9 11.21 MIR200B MIR200A MIR141
10 11.19 REN EDN1 AGTR1 AGT ACE
11
Show member pathways
11.07 REN NOS3 KNG1 AGTR1 AGT ACE2
12 10.79 GPR182 DBH ADM

GO Terms for Renal Hypertension

Cellular components related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.8 SLC12A3 NOS3 KNG1 EDN1 AGTR1 AGT
2 extracellular region GO:0005576 9.77 REN NPPB KNG1 KLKB1 EPO EDN1
3 extracellular space GO:0005615 9.47 REN NPPB MIR141 KNG1 KLKB1 EPO
4 blood microparticle GO:0072562 9.46 KNG1 APOL1 ALB AGT

Biological processes related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.06 MIR200B MIR141 EPO EDN1 AGT ADM
2 cell surface receptor signaling pathway GO:0007166 9.94 NPPB GPR182 EDN1 AGT
3 regulation of cell proliferation GO:0042127 9.91 DBH AGTR1 AGT ACE2
4 response to lipopolysaccharide GO:0032496 9.88 REN NOS3 EPO EDN1 ADM
5 kidney development GO:0001822 9.85 REN AGTR1 AGT ACE
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 KNG1 EDN1 AGTR1 AGT ADM
7 positive regulation of reactive oxygen species metabolic process GO:2000379 9.71 AGTR1 AGT ACE2
8 vasodilation GO:0042311 9.67 NOS3 KNG1 AGT
9 blood vessel remodeling GO:0001974 9.67 NOS3 DBH AGT ACE
10 amyloid-beta metabolic process GO:0050435 9.65 REN ACE
11 negative regulation of blood coagulation GO:0030195 9.65 KNG1 EDN1
12 positive regulation of urine volume GO:0035810 9.65 NPPB EDN1
13 low-density lipoprotein particle remodeling GO:0034374 9.64 AGTR1 AGT
14 artery smooth muscle contraction GO:0014824 9.63 EDN1 AGT
15 response to dexamethasone GO:0071548 9.63 EPO EDN1
16 positive regulation of renal sodium excretion GO:0035815 9.63 NPPB EDN1 AGT
17 regulation of blood pressure GO:0008217 9.63 REN NPPB NOS3 EDN1 AGT ACE
18 positive regulation of cholesterol esterification GO:0010873 9.62 AGTR1 AGT
19 body fluid secretion GO:0007589 9.62 NPPB EDN1
20 positive regulation of NAD(P)H oxidase activity GO:0033864 9.61 AGTR1 AGT
21 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.6 NOS3 EDN1
22 regulation of renal sodium excretion GO:0035813 9.59 AGTR1 AGT
23 positive regulation of gap junction assembly GO:1903598 9.58 AGT ACE2
24 angiotensin maturation GO:0002003 9.58 REN ACE2 ACE
25 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.57 AGTR1 AGT
26 regulation of blood volume by renin-angiotensin GO:0002016 9.56 REN AGT
27 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.56 AGTR1 AGT ACE2 ACE
28 angiotensin-mediated drinking behavior GO:0003051 9.52 AGT ACE2
29 regulation of renal output by angiotensin GO:0002019 9.51 AGT ACE
30 renin-angiotensin regulation of aldosterone production GO:0002018 9.5 REN AGTR1 AGT
31 regulation of vasoconstriction GO:0019229 9.35 EDN1 AGTR1 AGT ACE2 ACE
32 regulation of blood vessel diameter GO:0097746 9.02 NPPB NOS3 AGTR1 ACE2 ACE

Molecular functions related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 REN NPPB KNG1 EDN1 ADM
2 endopeptidase activity GO:0004175 9.54 REN ACE2 ACE
3 dipeptidyl-peptidase activity GO:0008239 9.4 ACE2 ACE
4 exopeptidase activity GO:0008238 9.32 ACE2 ACE
5 peptidyl-dipeptidase activity GO:0008241 9.16 ACE2 ACE
6 hormone activity GO:0005179 9.02 NPPB EPO EDN1 AGT ADM
7 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Renal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....